RT Journal Article
SR Electronic
T1 High Initial Heart Rate Score is an Independent Predictor of New Atrial High-Rate Episodes in Pacemaker Patients with Sinus Node Dysfunction
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.07.24302470
DO 10.1101/2024.02.07.24302470
A1 Hayashi, Katsuhide
A1 Abe, Haruhiko
A1 Olshansky, Brian
A1 Sharma, Arjun D.
A1 Jones, Paul W.
A1 Wold, Nicholas
A1 Perschbacher, David
A1 Kohno, Ritsuko
A1 Lip, Gregory Y. H.
A1 Wilkoff, Bruce L.
YR 2024
UL http://medrxiv.org/content/early/2024/02/08/2024.02.07.24302470.abstract
AB Background Heart Rate Score (HRSc), the percent of atrial beats in the largest paced/sensed 10-bpm histogram bin recorded in cardiac devices, is a metric of chronotropic incompetence. It remains uncertain if HRSc independently predicts atrial high-rate episodes (AHREs) in patients with sinus node dysfunction (SND) undergoing pacemaker (PM) implantation.Objective To determine the relationship between initial HRSc post-PM implant and new-onset AHREs in patients with SND.Methods The cohort included patients with Boston Scientific PMs implanted for SND from 2012-2021 at Cleveland Clinic, University of Occupational and Environmental Health, Japan, Kyushu Rosai Hospital, and JCHO Kyushu Hospital. Patients were excluded if they had atrial fibrillation before PM implant or AHREs in the initial 3-months post-implant. Subsequent AHREs post-implant (>1% of atrial beats>170 bpm) were evaluated.Results Over 48.9 (IQR 25.8-50.4) months, 136 consecutive PM patients (age 75±10 years, 42% male) were followed. The median initial HRSc was 73(55-86)%. AHREs developed in 28/136 (21%). Although %RA pacing and HRSc correlated, rate-responsive pacing was associated with a HRSc only in the patients with high %RA pacing. Patients with HRSc≥80% had higher occurrence of AHREs than those with HRSc<80% (p=0.01, log-rank test). After adjusting for age, race, comorbidities, left ventricular ejection fraction, left atrial diameter, %RA/RV pacing, and rate-response programming, HRSc (HR:2.84, 95% CI:1.17-6.92; P=0.02) and male sex (HR:2.55, 95% CI:1.15-6.19; P=0.04) were independent predictors of AHREs.Conclusion HRSc≥80% independently predicted new-onset, device-determined AHREs for patients undergoing PM implant for SND. HRSc may have prognostic and therapeutic implications.Competing Interest StatementThe authors have declared no competing interest.Funding StatementKatsuhide Hayashi and Ritsuko Kohno: have nothing to declare. Haruhiko Abe: Research Grant: Boston Scientific, Medtronic, Abbott Brian Olshansky: Member of a DSMB sponsored by AstraZeneka Arjun D. Sharma: Consultant: VivaQuant, CardioSignal Paul W. Jones, Nicholas Wold, and David Perschbacher are salaried employees of Boston Scientific. Bruce L. Wilkoff: Consultant and Speaker: Boston Scientific, Medtronic, Abbott, Biotronik Gregory Y.H. Lip: Consultant and speaker: BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthos. He is a National Institute for Health and Care Research (NIHR) Senior Investigator and co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 899871.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of the Cleveland Clinic, study #23-326.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data underlying this article will be shared on reasonable request to the corresponding authors.